Logo image of MDA.CA

MDA SPACE LTD (MDA.CA) Stock Fundamental Analysis

TSX:MDA - Toronto Stock Exchange - CA55293N1096 - Common Stock - Currency: CAD

24.33  -0.43 (-1.74%)

Fundamental Rating

5

Taking everything into account, MDA scores 5 out of 10 in our fundamental rating. MDA was compared to 12 industry peers in the Aerospace & Defense industry. MDA has an average financial health and profitability rating. MDA is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year MDA was profitable.
MDA had a positive operating cash flow in the past year.
MDA.CA Yearly Net Income VS EBIT VS OCF VS FCFMDA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 50M -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.64%, MDA is in line with its industry, outperforming 45.45% of the companies in the same industry.
With an excellent Return On Equity value of 5.95%, MDA belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
MDA has a Return On Invested Capital of 3.80%. This is in the lower half of the industry: MDA underperforms 63.64% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MDA is below the industry average of 7.19%.
The last Return On Invested Capital (3.80%) for MDA is above the 3 year average (2.75%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.64%
ROE 5.95%
ROIC 3.8%
ROA(3y)1.32%
ROA(5y)N/A
ROE(3y)2.5%
ROE(5y)N/A
ROIC(3y)2.75%
ROIC(5y)N/A
MDA.CA Yearly ROA, ROE, ROICMDA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 2 -2 4

1.3 Margins

MDA has a Profit Margin of 7.22%. This is amongst the best in the industry. MDA outperforms 90.91% of its industry peers.
The Operating Margin of MDA (9.46%) is worse than 63.64% of its industry peers.
MDA has a better Gross Margin (27.45%) than 81.82% of its industry peers.
MDA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9.46%
PM (TTM) 7.22%
GM 27.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y23.95%
GM growth 5YN/A
MDA.CA Yearly Profit, Operating, Gross MarginsMDA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 10 20 30

4

2. Health

2.1 Basic Checks

MDA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for MDA has been increased compared to 1 year ago.
The debt/assets ratio for MDA is higher compared to a year ago.
MDA.CA Yearly Shares OutstandingMDA.CA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
MDA.CA Yearly Total Debt VS Total AssetsMDA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

MDA has an Altman-Z score of 1.70. This is a bad value and indicates that MDA is not financially healthy and even has some risk of bankruptcy.
MDA has a better Altman-Z score (1.70) than 72.73% of its industry peers.
The Debt to FCF ratio of MDA is 1.98, which is an excellent value as it means it would take MDA, only 1.98 years of fcf income to pay off all of its debts.
MDA has a better Debt to FCF ratio (1.98) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that MDA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.34, MDA is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 1.98
Altman-Z 1.7
ROIC/WACC0.49
WACC7.79%
MDA.CA Yearly LT Debt VS Equity VS FCFMDA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

MDA has a Current Ratio of 0.83. This is a bad value and indicates that MDA is not financially healthy enough and could expect problems in meeting its short term obligations.
MDA has a Current ratio of 0.83. This is amonst the worse of the industry: MDA underperforms 81.82% of its industry peers.
A Quick Ratio of 0.82 indicates that MDA may have some problems paying its short term obligations.
MDA has a Quick ratio of 0.82. This is amongst the best in the industry. MDA outperforms 81.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.82
MDA.CA Yearly Current Assets VS Current LiabilitesMDA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M

8

3. Growth

3.1 Past

MDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.33%, which is quite impressive.
The Revenue has grown by 18.99% in the past year. This is quite good.
MDA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.80% yearly.
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)18.99%
Revenue growth 3Y39.8%
Revenue growth 5YN/A
Sales Q2Q%37.96%

3.2 Future

MDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.47% yearly.
MDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.68% yearly.
EPS Next Y52.7%
EPS Next 2Y47.28%
EPS Next 3Y42.47%
EPS Next 5YN/A
Revenue Next Year30.6%
Revenue Next 2Y30.39%
Revenue Next 3Y26.68%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MDA.CA Yearly Revenue VS EstimatesMDA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
MDA.CA Yearly EPS VS EstimatesMDA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 42.68, the valuation of MDA can be described as expensive.
Based on the Price/Earnings ratio, MDA is valued a bit more expensive than 72.73% of the companies in the same industry.
When comparing the Price/Earnings ratio of MDA to the average of the S&P500 Index (29.39), we can say MDA is valued slightly more expensively.
With a Price/Forward Earnings ratio of 26.71, MDA can be considered very expensive at the moment.
72.73% of the companies in the same industry are cheaper than MDA, based on the Price/Forward Earnings ratio.
MDA is valuated cheaply when we compare the Price/Forward Earnings ratio to 94.38, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 42.68
Fwd PE 26.71
MDA.CA Price Earnings VS Forward Price EarningsMDA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

72.73% of the companies in the same industry are cheaper than MDA, based on the Enterprise Value to EBITDA ratio.
90.91% of the companies in the same industry are more expensive than MDA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.57
EV/EBITDA 18.1
MDA.CA Per share dataMDA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

MDA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MDA's earnings are expected to grow with 42.47% in the coming years.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y47.28%
EPS Next 3Y42.47%

0

5. Dividend

5.1 Amount

MDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

MDA SPACE LTD

TSX:MDA (2/11/2025, 7:00:00 PM)

24.33

-0.43 (-1.74%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst Owners29.14%
Inst Owner ChangeN/A
Ins Owners1.21%
Ins Owner ChangeN/A
Market Cap2.93B
Analysts76.67
Price Target33.79 (38.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.65%
Min EPS beat(2)-9.44%
Max EPS beat(2)56.74%
EPS beat(4)3
Avg EPS beat(4)38.42%
Min EPS beat(4)-9.44%
Max EPS beat(4)99.25%
EPS beat(8)7
Avg EPS beat(8)44.46%
EPS beat(12)10
Avg EPS beat(12)86.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)0.84%
Max Revenue beat(2)8.65%
Revenue beat(4)2
Avg Revenue beat(4)1.64%
Min Revenue beat(4)-2.45%
Max Revenue beat(4)8.65%
Revenue beat(8)6
Avg Revenue beat(8)2.01%
Revenue beat(12)8
Avg Revenue beat(12)1.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.74%
PT rev (3m)82.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.38%
EPS NY rev (1m)0%
EPS NY rev (3m)23.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.88%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)1.14%
Valuation
Industry RankSector Rank
PE 42.68
Fwd PE 26.71
P/S 3.12
P/FCF 14.57
P/OCF 7.49
P/B 2.57
P/tB 24.76
EV/EBITDA 18.1
EPS(TTM)0.57
EY2.34%
EPS(NY)0.91
Fwd EY3.74%
FCF(TTM)1.67
FCFY6.86%
OCF(TTM)3.25
OCFY13.35%
SpS7.79
BVpS9.46
TBVpS0.98
PEG (NY)0.81
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.64%
ROE 5.95%
ROCE 5.09%
ROIC 3.8%
ROICexc 4.13%
ROICexgc 11.37%
OM 9.46%
PM (TTM) 7.22%
GM 27.45%
FCFM 21.44%
ROA(3y)1.32%
ROA(5y)N/A
ROE(3y)2.5%
ROE(5y)N/A
ROIC(3y)2.75%
ROIC(5y)N/A
ROICexc(3y)2.82%
ROICexc(5y)N/A
ROICexgc(3y)9.08%
ROICexgc(5y)N/A
ROCE(3y)3.67%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y23.95%
GM growth 5YN/A
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 1.98
Debt/EBITDA 2.18
Cap/Depr 217.26%
Cap/Sales 20.26%
Interest Coverage 3.55
Cash Conversion 221.95%
Profit Quality 296.76%
Current Ratio 0.83
Quick Ratio 0.82
Altman-Z 1.7
F-Score5
WACC7.79%
ROIC/WACC0.49
Cap/Depr(3y)200.76%
Cap/Depr(5y)N/A
Cap/Sales(3y)23.95%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y52.7%
EPS Next 2Y47.28%
EPS Next 3Y42.47%
EPS Next 5YN/A
Revenue 1Y (TTM)18.99%
Revenue growth 3Y39.8%
Revenue growth 5YN/A
Sales Q2Q%37.96%
Revenue Next Year30.6%
Revenue Next 2Y30.39%
Revenue Next 3Y26.68%
Revenue Next 5YN/A
EBIT growth 1Y10.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year169.29%
EBIT Next 3Y63.03%
EBIT Next 5YN/A
FCF growth 1Y276.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y601.25%
OCF growth 3Y-37.91%
OCF growth 5YN/A